Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Strides is the first Indian company to get approval for the product.
Subscribe To Our Newsletter & Stay Updated
